Navigation Links
Results of First Interim Efficacy Analysis for Riquent Phase 3 ASPEN Trial: Continuation of the Trial is Futile
Date:2/12/2009

ion of Merck KGaA of Darmstadt, Germany. Other product candidates include 6R-BH4 for cardiovascular indications, which is currently in Phase 2 clinical development for the treatment of sickle cell disease, and PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase 1 clinical development for the treatment of PKU. For additional information, please visit http://www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

Forward-Looking Statement

This press release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including, without limitation, statements about: expectations related to the clinical trials and continued development of abetimus sodium, also known as Riquent. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others: results and timing of current and planned preclinical studies and clinical trials, including the ASPEN study; the enrollment rate of such study and the actual rate of renal flares in such study; the content and timing of decisions by the U.S. Food and Drug Administration, the European Commission regarding abetimus sodium; La Jolla Pharmaceutical's ability to and success in executing the ASPEN study and its ability to produce sufficient quantities of material for such study; and those factors detailed in BioMarin's filings with the Securities and Exchange Commission, including, without limitation, the factors contained under the caption "Risk Factors" in BioMarin's 2007 Annual Report on Form 10-K, and the factors contained in BioMarin's reports on Form 10-Q. Stockholders are urged not to place undue reliance on forward-looking statements, which speak only as of the date
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
4. CNS Response Announces Fiscal Third Quarter 2007 Results
5. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
8. Carrington Reports Second Quarter 2007 Results
9. Avitar Reports Third Quarter Financial Results for Fiscal 2007
10. Response Genetics Reports Second Quarter 2007 Financial Results
11. Martek to Announce Third Quarter 2007 Results on September 5, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... ... 02, 2015 , ... Genedata, a leading provider of advanced ... Screener ® version 13.0 at ELRIG Drug Discovery 2015. This latest version of ... of new capabilities. Screener now supports High Throughput Flow Cytometry (HT-Flow) and Drug ...
(Date:9/1/2015)... The American Brain Tumor Association (ABTA) is ... Research Grant program. LOIs are due no later than ... Discovery Grants are one-year, $50,000 grants that fund ... current diagnostic or treatment paradigms for adults and children ... at its earliest stages, in the hopes that it ...
(Date:9/1/2015)... (PRWEB) , ... September 01, ... ... the launch of the new ImageXpress® Micro Confocal High-Content Imaging System. This ... emerging assays that use 3D cellular models such as spheroids, tissues, and ...
(Date:9/1/2015)... ... September 01, 2015 , ... VetStem Biopharma announces new Clinical ... joint problems can be caused by injuries and abnormalities of the cervical spine. ... or of the spinal cord itself. This can manifest itself as any or ...
Breaking Biology Technology:New Genedata Screener 13.0 with Support for High Throughput Flow Cytometry and DMPK Unveiled at ELRIG 2New Genedata Screener 13.0 with Support for High Throughput Flow Cytometry and DMPK Unveiled at ELRIG 3New Genedata Screener 13.0 with Support for High Throughput Flow Cytometry and DMPK Unveiled at ELRIG 4American Brain Tumor Association Seeks Innovative Concepts For Discovery Research Grants 2ImageXpress Micro Confocal High-Content Imaging System Expands the Boundaries of Research 2ImageXpress Micro Confocal High-Content Imaging System Expands the Boundaries of Research 3VetStem Biopharma Announces New Clinical Research Program for Equine Cervical Facet Joint Disease 2VetStem Biopharma Announces New Clinical Research Program for Equine Cervical Facet Joint Disease 3
... , , FRAMINGHAM, ... HTWR ) (ASX: HIN) today confirmed that trading ... Exchange ("ASX") was temporarily suspended for the reasons stated below. ... NASDAQ is also temporarily suspended. Based on discussions with ...
... , ANNAPOLIS, Md., Sept. 1 PharmAthene, Inc. ... medical countermeasures against biological and chemical threats, announced today that ... Investment Conference 2009. The Company is scheduled to present ... the Hubbard Salon (5th Floor) at the New York Palace ...
... , , DALLAS, Sept. 1 ... (OTC Bulletin Board : ACCP) announced today that ... be held September 9-11, 2009 at the New York Palace Hotel in New ... to speak on Friday, September 11, 2009 at 10:50 am EDT in the ...
Cached Biology Technology:HeartWare International, Inc. Temporary Suspension of Trading 2HeartWare International, Inc. Temporary Suspension of Trading 3Access Pharmaceuticals to Present at the Rodman & Renshaw Annual Healthcare Conference 2Access Pharmaceuticals to Present at the Rodman & Renshaw Annual Healthcare Conference 3
(Date:8/18/2015)... 2015  Navitas today announced that it ... Submission Content Management webinar scheduled on August ... to the Implementation of Regulatory Submission Standards ... industry, vendors, health authorities, consultants and the ... a standard method of implementing electronic submission ...
(Date:8/12/2015)... Aug. 12, 2015   MedNet Solutions , an ... spectrum of clinical research, is proud to announce that ... comprehensive SaaS-based eClinical technology platform, has led the way ... two quarters of 2015.   Q2 2015 and Q1 ... measured by contract value sold in the company,s 15 ...
(Date:8/12/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), ... announced that four of its fingerprint ID products, ... been named FIDO Certified™ by the Fast IDentity ... Synaptics, Natural ID™ fingerprint solutions are fully compliant ... standard and are interoperable among other products and ...
Breaking Biology News(10 mins):Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3MedNet Solutions Experiences Explosive Corporate Growth 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3
... Miami,s Rosenstiel School of Marine and Atmospheric Science ... Jimenez, Ph.D., as recipient of the 2010 Rosenstiel ... and Fellow of the Cooperative Institute for Research ... of Colorado, his work applies groundbreaking measurement techniques ...
... National Science Foundation has bestowed a Faculty Early Career ... a molecular biologist and geneticist whose work since she ... both her passion for research and her commitment to ... CAREER Award is an exceptional recognition of exceptional qualities ...
... than 40 years ago, Galenia pubescens , an exotic ... altered coastal environments in the south of Spain. Since its ... has studied its invasive capacity. The conclusions of this study ... incipient levels, effective control is needed to prevent this "potentially" ...
Cached Biology News:Dr. Jose L. Jimenez to receive 2010 UM Rosenstiel Award 2FSU biologist wins $1M Early Career Award from National Science Foundation 2FSU biologist wins $1M Early Career Award from National Science Foundation 3Exotic plant takes over dunes of Southern Spain 2
Mouse polyclonal antibody raised against a partial recombinant CSRP3. NCBI Entrez Gene ID = 8048...
Mouse monoclonal antibody raised against a partial recombinant EOMES. NCBI Entrez Gene ID = EOMES...
...
... 2-D Sample Preparation for Membrane Proteins ... 25 membrane,protein extracts for 2-D gel analysis ... Protein Extraction Kit , (contains ... with a packed cell weight of 10 ...
Biology Products: